Docoh
Loading...

VREX Varex Imaging

Cover

Cover - shares6 Months Ended
Apr. 02, 2021Apr. 27, 2021
Cover [Abstract]
Document Type10-Q
Document Quarterly Reporttrue
Document Period End DateApr. 2,
2021
Document Transition Reportfalse
Entity File Number001-37860
Entity Registrant NameVAREX IMAGING CORPORATION
Entity Incorporation, State or Country CodeDE
Entity Tax Identification Number81-3434516
Entity Address, Address Line One1678 S. Pioneer Road
Entity Address, City or TownSalt Lake City
Entity Address, State or ProvinceUT
Entity Address, Postal Zip Code84104
City Area Code801
Local Phone Number972-5000
Title of 12(b) SecurityCommon Stock
Trading SymbolVREX
Security Exchange NameNASDAQ
Entity Current Reporting StatusYes
Entity Interactive Data CurrentYes
Entity Filer CategoryLarge Accelerated Filer
Smaller Reporting Companyfalse
Emerging Growth Companyfalse
Entity Shell Companyfalse
Entity Common Stock, Shares Outstanding (in shares)39,300,000
Amendment Flagfalse
Document Fiscal Year Focus2021
Document Fiscal Period FocusQ2
Entity Central Index Key0001681622
Current Fiscal Year End Date--10-01

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Income Statement [Abstract]
Revenues, net $ 203.5 $ 197 $ 380.6 $ 397.1
Cost of revenues138.9 139.4 258.8 278.4
Gross profit64.6 57.6 121.8 118.7
Operating expenses:
Research and development18.2 20.9 34.9 42.6
Selling, general and administrative30.6 35.3 65 70.1
Total operating expenses48.8 56.2 99.9 112.7
Operating income15.8 1.4 21.9 6
Interest income0 0.1 0 0.1
Interest expense(10.4)(4.6)(20.7)(10)
Other (expense) income, net(2.2)2 (2.7)1.6
Interest and other expense, net(12.6)(2.5)(23.4)(8.3)
Income (loss) before taxes3.2 (1.1)(1.5)(2.3)
Income tax expense0 0.7 1.6 0.7
Net income (loss)3.2 (1.8)(3.1)(3)
Less: Net income attributable to noncontrolling interests0.1 0.1 0.2 0.2
Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (3.2)
Net income (loss) per common share attributable to Varex
Basic (in USD per share) $ 0.08 $ (0.05) $ (0.09) $ (0.08)
Diluted (in USD per share) $ 0.08 $ (0.05) $ (0.09) $ (0.08)
Weighted average common shares outstanding
Basic (in shares)39.2 38.6 39.2 38.5
Diluted (in shares)40 38.6 39.2 38.5

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME LOSS (Unaudited) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss) $ 3.2 $ (1.8) $ (3.1) $ (3)
Other comprehensive (loss) income, net of tax:
Unrealized loss on interest rate swap contracts0 (2.3)0 (2.3)
Foreign currency translation adjustments(0.7)5.2 (0.6)4.3
Other comprehensive (loss) income, net of tax(0.7)2.9 (0.6)2
Comprehensive income (loss)2.5 1.1 (3.7)(1)
Less: Comprehensive income attributable to noncontrolling interests0.1 0.1 0.2 0.2
Comprehensive income (loss) attributable to Varex $ 2.4 $ 1 $ (3.9) $ (1.2)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Current assets:
Cash and cash equivalents $ 111.1 $ 100.6
Accounts receivable, net of allowance for credit losses of $0.8 million and $0.3 million at April 2, 2021 and October 2, 2020, respectively129.1 123.8
Inventories248.2 271.9
Prepaid expenses and other current assets41.4 25.7
Total current assets529.8 522
Property, plant and equipment, net142.2 145.2
Goodwill293.3 293.1
Intangible assets, net59.2 67.5
Investments in privately-held companies49 51.3
Deferred tax assets0 0.5
Operating lease right-of-use assets26.9 27.7
Other assets32.2 32.2
Total assets1,132.6 1,139.5
Current liabilities:
Accounts payable51.8 72.9
Accrued liabilities and other current liabilities76.6 70.5
Current operating lease liabilities6.2 6.1
Current maturities of long-term debt2.9 2.5
Deferred revenues8.8 8.6
Total current liabilities146.3 160.6
Long-term debt, net458 452.8
Deferred tax liabilities2.2 2.3
Operating lease liabilities22 23.1
Other long-term liabilities35.2 34.9
Total liabilities663.7 673.7
Stockholders' equity:
Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued0 0
Common stock, $.01 par value: 150,000,000 shares authorized, shares issued and outstanding - 39,300,288 and 39,059,094 at April 2, 2021 and October 2, 2020, respectively0.4 0.4
Additional paid-in capital441.3 434.4
Accumulated other comprehensive income0.2 0.8
Retained earnings12.8 16.1
Total Varex equity454.7 451.7
Noncontrolling interests14.2 14.1
Total stockholders' equity468.9 465.8
Total liabilities and stockholders' equity $ 1,132.6 $ 1,139.5

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts $ 0.8 $ 0.3
Preferred stock, par value (in USD per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares)20,000,000 20,000,000
Preferred stock, shares issued (in shares)0 0
Common stock, par value per share (in USD per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares)150,000,000 150,000,000
Common stock, shares, issued (in shares)39,300,288 39,059,094
Common stock, shares, outstanding (in shares)39,300,288 39,059,094

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions6 Months Ended
Apr. 02, 2021Apr. 03, 2020
Cash flows from operating activities:
Net loss $ (3.1) $ (3)
Adjustments to reconcile net loss to net cash provided by operating activities:
Share-based compensation expense7.2 6.5
Depreciation10.5 11.4
Amortization of intangible assets8.5 8.9
Deferred taxes0.1 0.3
Loss from equity method investments2.5 0.7
Amortization of debt issuance costs and discounts4.9 1.2
Inventory write-down3.5 0
Other, net1 0.2
Changes in assets and liabilities, net of effects of acquisition:
Accounts receivable(6.2)14.7
Inventories20.4 (34.2)
Prepaid expenses and other assets(15.1)(5.9)
Accounts payable(19.8)21
Accrued liabilities and other current and long-term operating liabilities5.2 0.9
Deferred revenues0.3 1.2
Net cash provided by operating activities19.9 23.9
Cash flows from investing activities:
Purchases of property, plant and equipment(7.8)(14.2)
Acquisitions of businesses, net of cash acquired0 (1.2)
Investments and loans to privately-held companies(0.6)(1.9)
Net cash used in investing activities(8.4)(17.3)
Cash flows from financing activities:
Borrowings under credit agreements1.5 23.5
Repayments of borrowing under credit agreements(1.5)(36.5)
Payment of debt issuance costs0 (0.5)
Proceeds from exercise of stock options0 1.5
Proceeds from shares issued under employee stock purchase plan1.2 1.8
Taxes related to net share settlement of equity awards(1.5)(1.8)
Other financing activities(0.7)(0.1)
Net cash used in financing activities(1)(12.1)
Effects of exchange rate changes on cash and cash equivalents and restricted cash0 (0.2)
Net increase (decrease) in cash and cash equivalents and restricted cash10.5 (5.7)
Cash and cash equivalents and restricted cash at beginning of period102.1 31.3
Cash and cash equivalents and restricted cash at end of period112.6 25.6
Supplemental cash flow information:
Cash paid for interest4 9.2
Cash paid for income tax12.9 6.4
Supplemental non-cash activities:
Purchases of property, plant and equipment financed through accounts payable $ 0.4 $ 0.9

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited) - USD ($) $ in MillionsTotalCumulative Effect, Period of Adoption, AdjustmentCommon StockAdditional Paid-in CapitalAccumulated Other Comprehensive LossRetained EarningsRetained EarningsCumulative Effect, Period of Adoption, AdjustmentTotal Varex EquityTotal Varex EquityCumulative Effect, Period of Adoption, AdjustmentNoncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes $ 448.2 $ (0.3) $ 0.4 $ 371.8 $ (1.7) $ 74.4 $ (0.3) $ 444.9 $ (0.3) $ 3.3
Common stock, shares, outstanding, beginning balance (in shares) at Sep. 27, 201938,400,000
Stockholders' equity, beginning balance at Sep. 27, 2019448.2 (0.3) $ 0.4 371.8 (1.7)74.4 (0.3)444.9 (0.3)3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes448.2 (0.3) $ 0.4 371.8 (1.7)70.9 (0.3)444.9 (0.3)3.3
Net income (loss)(3)
Net income (loss)(3.3)(3.2)(3.2)(0.1)
Exercise of stock options (in shares)100,000
Exercise of stock options1.5 1.5 1.5
Common stock issued upon vesting of restricted shares (in shares)200,000
Common stock issued upon vesting of restricted shares0
Shares withheld on vesting of restricted stock (in shares)(100,000)
Shares withheld on vesting of restricted stock(1.8)(1.8)(1.8)
Common stock issued under employee stock purchase plan (in shares)100,000
Common stock issued under employee stock purchase plan1.8 1.8 1.8
Share-based compensation6.5 6.5 6.5
Unrealized loss on interest rate swap contracts, net of tax(2.3)(2.3)(2.3)
Currency translation adjustments4.3 4.3 4.3
Other(0.3)(0.3)(0.3)
Common stock, shares, outstanding, ending balance (in shares) at Apr. 03, 202038,700,000
Stockholders' equity, ending balance at Apr. 03, 2020454.3 $ 0.4 379.5 0.3 70.9 451.1 3.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes451.2 0.3 $ 0.4 377.6 (2.6)72.5 0.3 447.9 0.3 3.3
Common stock, shares, outstanding, beginning balance (in shares) at Jan. 03, 202038,500,000
Stockholders' equity, beginning balance at Jan. 03, 2020451.2 0.3 $ 0.4 377.6 (2.6)72.5 0.3 447.9 0.3 3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes454.3 $ 0.3 $ 0.4 379.5 0.3 70.9 $ 0.3 451.1 $ 0.3 3.2
Net income (loss)(1.8)
Net income (loss)(2)(1.9)(1.9)(0.1)
Exercise of stock options0.3 0.3 0.3
Common stock issued upon vesting of restricted shares (in shares)200,000
Common stock issued upon vesting of restricted shares0
Shares withheld on vesting of restricted stock(1.7)(1.7)(1.7)
Share-based compensation3.3 3.3 3.3
Unrealized loss on interest rate swap contracts, net of tax(2.3)(2.3)(2.3)
Currency translation adjustments5.2 5.2 5.2
Common stock, shares, outstanding, ending balance (in shares) at Apr. 03, 202038,700,000
Stockholders' equity, ending balance at Apr. 03, 2020454.3 $ 0.4 379.5 0.3 70.9 451.1 3.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes454.3 0.4 379.5 0.3 70.9 451.1 3.2
Cumulative effect of accounting changes $ 465.8 $ 0.4 434.4 0.8 16.1 451.7 14.1
Common stock, shares, outstanding, beginning balance (in shares) at Oct. 02, 202039,059,094 39,100,000
Stockholders' equity, beginning balance at Oct. 02, 2020 $ 465.8 $ 0.4 434.4 0.8 16.1 451.7 14.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes465.8 $ 0.4 441.3 0.2 12.8 454.7 14.1
Net income (loss) $ (3.1)(3.3)(3.3)0.2
Exercise of stock options (in shares)0
Common stock issued upon vesting of restricted shares (in shares)200,000
Common stock issued upon vesting of restricted shares $ 0
Shares withheld on vesting of restricted stock (in shares)(100,000)
Shares withheld on vesting of restricted stock(1.5)(1.5)(1.5)
Common stock issued under employee stock purchase plan (in shares)100,000
Common stock issued under employee stock purchase plan1.2 1.2 1.2
Share-based compensation7.2 7.2 7.2
Currency translation adjustments(0.6)(0.6)(0.6)
Other $ (0.1)(0.1)
Common stock, shares, outstanding, ending balance (in shares) at Apr. 02, 202139,300,288 39,300,000
Stockholders' equity, ending balance at Apr. 02, 2021 $ 468.9 $ 0.4 441.3 0.2 12.8 454.7 14.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes464.4 $ 0.4 439.2 0.9 9.7 450.2 14.2
Common stock, shares, outstanding, beginning balance (in shares) at Jan. 01, 202139,200,000
Stockholders' equity, beginning balance at Jan. 01, 2021464.4 $ 0.4 439.2 0.9 9.7 450.2 14.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes464.4 $ 0.4 441.3 0.2 12.8 454.7 14.2
Net income (loss)3.2 3.1 3.1 0.1
Common stock issued upon vesting of restricted shares (in shares)200,000
Common stock issued upon vesting of restricted shares0
Shares withheld on vesting of restricted stock (in shares)(100,000)
Shares withheld on vesting of restricted stock(1.5)(1.5)(1.5)
Share-based compensation3.6 3.6 3.6
Currency translation adjustments(0.7)(0.7)(0.7)
Other $ (0.1)(0.1)
Common stock, shares, outstanding, ending balance (in shares) at Apr. 02, 202139,300,288 39,300,000
Stockholders' equity, ending balance at Apr. 02, 2021 $ 468.9 $ 0.4 441.3 0.2 12.8 454.7 14.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes $ 468.9 $ 0.4 $ 441.3 $ 0.2 $ 12.8 $ 454.7 $ 14.2

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES6 Months Ended
Apr. 02, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESSUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of medical products, which include X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary equipment, to independent service companies, distributors and directly to end-users for replacement purposes. The Company also designs, manufacturers, sells and services industrial products, which include Linatron® X-ray accelerators, high voltage connectors, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods. These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended 2020 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 30, 2020. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, Summary of Significant Accounting Policies, in the Company’s Annual Report on Form 10-K for fiscal year 2020. Segment Reporting The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15. Segment Information , for further information on the Company’s segments. Fiscal Year The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2021 is the 52-week period ending October 1, 2021. Fiscal year 2020 was the 53-week period that ended on October 2, 2020. The fiscal quarters ended April 2, 2021 and April 3, 2020 were both 13-week periods. The two fiscal quarters ended April 2, 2021 and April 3, 2020 were 26 weeks and 27 weeks, respectively. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, warranties, contract liabilities, long-lived asset valuations, impairment on investments, valuation of financial instruments, and taxes on earnings. Actual results could differ from these estimates. Impact of COVID-19 The coronavirus (“COVID-19”) pandemic and the mitigation efforts by governments to control its spread have created uncertainties and disruptions in the economic and financial markets. The extent to which COVID-19 will continue to impact the Company’s business and financial results depends on numerous evolving factors including: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates and unemployment rates, the speed of the economic recovery, and governmental and business reactions to the pandemic. As a result of the economic downturn resulting from COVID-19, the Company experienced reduced demand in its Industrial segment and for certain higher-end medical products that negatively impacted revenues and gross margin. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company, including the estimated future impacts of COVID-19 through the date of filing this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangibles, long-lived assets, equity method investments, inventory and related reserves, and allowance for credit losses. The Company’s assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material negative impacts to the Company’s condensed consolidated financial statements in future reporting periods. These future developments are highly uncertain and the outcomes cannot be estimated with certainty. Actual results may differ from those estimates, and such differences may be material to the financial statements. Cash and Cash Equivalents The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Restricted Cash Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the condensed consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following: Six Months Ended April 2, 2021 Six Months Ended April 3, 2020 (In millions) Beginning of Period End of Period Beginning of Period End of Period Cash and cash equivalents $ 100.6 $ 111.1 $ 29.9 $ 24.2 Restricted cash 1.5 1.5 1.4 1.4 Cash and cash equivalents and restricted cash as reported per statement of cash flows $ 102.1 $ 112.6 $ 31.3 $ 25.6 Concentration of Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for credit losses based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration. Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's customers accounted for a significant portion of revenues, which is as follows: Three Months Ended Six Months Ended April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Canon Medical Systems Corporation 17.8 % 23.0 % 17.2% 20.9% Canon Medical Systems Corporation accounted for 14.6% and 12.0% of the Company’s consolidated accounts receivable as of April 2, 2021 and October 2, 2020, respectively. Investments The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach, which means that distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment and classified as operating cash flows and those in excess of that amount will be treated as returns of investment and classified as investing cash flows. The Company reviews its equity investments in privately-held companies for impairment whenever events or changes in business circumstances are other than temporary and indicate that the carrying amount of the investments may not be fully recoverable. There were no impairments recorded during the three and six months ended April 2, 2021 and April 3, 2020, respectively. Loss Contingencies From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed. Product Warranty The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while under warranty. The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required. The following table reflects the changes in the Company’s accrued product warranty: Six Months Ended (In millions) April 2, 2021 April 3, 2020 Accrued product warranty, at beginning of period $ 8.1 $ 8.1 New accruals charged to cost of revenues 6.1 7.2 Product warranty expenditures (6.3) (6.9) Accrued product warranty, at end of period $ 7.9 $ 8.4 Leases The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Revenue Recognition The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products. The Company determines revenue recognition through the following steps: • Identification of the contract, or contracts, with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations in the contract • Recognition of revenue when, or as, a performance obligation is satisfied Transaction price and allocation to performance obligations Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. Contracts and performance obligations The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations. Recognition of revenue Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer. Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer. Disaggregation of Revenue Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15. Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2. Revenue for the disaggregation of revenue by geographic region. Contract Balances Contract assets are included within the prepaid expenses and other current assets, and other assets balances in the condensed consolidated balance sheets. Contract liabilities, which also include refund obligations, are included within the accrued liabilities and other current liabilities, deferred revenues, and other long-term liabilities balances in the condensed consolidated balance sheets. Costs to Obtain or Fulfill a Customer Contract The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over more than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues. Deferred Revenues Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for which the services have not been rendered. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Measurement of Credit Losses on Financial Instruments. This pronouncement changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans and replaces the incurred loss methodology with a new, forward-looking “expected loss” model that considers the risk of loss over the asset’s contractual life, even if remote, historical experience, current conditions, and reasonable and supportable forecasts of future relevant events. The Company adopted this ASU on October 3, 2020, using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. Recent Accounting Standards or Updates Not Yet Effective In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The standard removes certain separation models in ASC 470-20 for convertible instruments, and, as a result, embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under ASC 815. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate. Further, the ASU made amendments to the earnings per share (“EPS”) guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. We are currently evaluating the impacts of this ASU on our condensed consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting, to provide optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate (e.g., LIBOR) reform on financial reporting. Adoption of the guidance is elective and is permitted from March 12, 2020 through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The Company does not expect that the new guidance will have a material impact on its financial position, results of operations or cash flows. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.

REVENUE

REVENUE6 Months Ended
Apr. 02, 2021
Revenue from Contract with Customer [Abstract]
REVENUEREVENUE Disaggregation of Revenue Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. The following table disaggregates the Company’s revenue by geographic region: Three Months Ended Six Months Ended (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Americas $ 70.5 $ 62.5 $ 132.8 $ 132.8 EMEA 67.7 64.0 125.6 129.2 APAC 65.3 70.5 122.2 135.1 $ 203.5 $ 197.0 $ 380.6 $ 397.1 Revenue in the United States of America was $69.2 million and $60.2 million for the three months ended April 2, 2021 and April 3, 2020, respectively. Revenue in the United States of America was $130.3 million and $128.8 million for the six months ended April 2, 2021 and April 3, 2020, respectively. Refer to Note 15, Segment Information , for the disaggregation of the Company’s revenue based on reportable operating segments. Contract Balances The following table summarizes the changes in the contract assets and refund liabilities: Contract Assets Six Months Ended (In millions) April 2, 2021 April 3, 2020 Balance at beginning of fiscal year $ 24.6 $ 23.7 Costs recovered from product returns during the period (2.4) (3.0) Contract asset from shipments of products, subject to return during the period 2.9 3.4 Change in estimate (0.6) — Balance at end of period $ 24.5 $ 24.1 Contract Liabilities Six Months Ended (In millions) April 2, 2021 April 3, 2020 Balance at beginning of fiscal year $ 27.4 $ 26.4 Release of refund liability included in beginning of year refund liability (2.7) (3.3) Additions to refund liabilities 3.2 3.8 Change in estimate (0.7) — Balance at end of period $ 27.2 $ 26.9 During the three and six months ended April 2, 2021, the Company recognized revenue of $0.4 million and $5.4 million related to deferred revenues which existed at October 2, 2020. During the three and six months ended April 3, 2020, the Company recognized revenue of $1.3 million and $7.4 million related to deferred revenue which existed at September 27, 2019.

LEASES

LEASES6 Months Ended
Apr. 02, 2021
Leases [Abstract]
LEASESLEASES The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: (In millions) Balance Sheet Location April 2, 2021 October 2, 2020 Assets Operating lease right-of-use assets Operating lease right-of-use assets $ 26.9 $ 27.7 Finance lease right-of-use assets Property, plant and equipment, net $ 0.5 $ 0.5 Liabilities Operating lease liabilities (current) Current operating lease liabilities $ 6.2 $ 6.1 Finance lease liabilities (current) Accrued liabilities and other current liabilities $ 0.3 $ 0.2 Operating lease liabilities (non-current) Operating lease liabilities $ 22.0 $ 23.1 Finance lease liabilities (non-current) Other long-term liabilities $ 0.3 $ 0.4 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: April 2, 2021 April 3, 2020 Operating lease weighted average remaining lease term (in years) 6.2 6.8 Operating lease weighted average discount rate 4.9 % 4.9 % Finance lease weighted average remaining lease term (in years) 3.0 3.2 Finance lease weighted average discount rate 3.8 % 3.6 % The following table provides information related to the Company’s operating and finance leases: (In millions) Three Months Ended April 2, 2021 Three Months Ended April 3, 2020 Six Months Ended April 2, 2021 Six Months Ended April 3, 2020 Total operating lease costs (a) $ 2.0 $ 1.9 $ 3.9 $ 4.0 Total finance lease costs $ — $ 0.1 $ 0.1 $ 0.1 Operating cash flows from operating leases $ 1.9 $ 2.1 $ 3.7 $ 4.1 Financing cash flows from finance leases — (0.1) 0.1 — Total cash paid for amounts included in the measurement of lease liabilities $ 1.9 $ 2.0 $ 3.8 $ 4.1 (a) Includes variable and short-term lease expense, which were immaterial for the three and six months ended April 2, 2021 and April 3, 2020. As of April 2, 2021, the present value of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows: (In millions) Fiscal years: Operating Leases Finance Leases 2021 remaining $ 3.7 $ 0.1 2022 7.2 0.2 2023 4.8 0.2 2024 4.1 0.1 2025 3.8 — Thereafter 9.4 — Total future lease payments $ 33.0 $ 0.6 Less: imputed interest (4.8) — Present value of lease liabilities $ 28.2 $ 0.6 During the first quarter of fiscal year 2021, the Company entered into a lease agreement for a manufacturing facility in the Philippines that consists of three buildings. During the second quarter of fiscal year 2021, the Company commenced leasing one of the three buildings. The leases for the other two buildings are not expected to commence until the third quarter of fiscal year 2021. These remaining two building leases have a stated term of five years and will result in an initial lease right-of-use asset and liability balance of approximately $2.4 million upon lease commencement.
LEASESLEASES The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: (In millions) Balance Sheet Location April 2, 2021 October 2, 2020 Assets Operating lease right-of-use assets Operating lease right-of-use assets $ 26.9 $ 27.7 Finance lease right-of-use assets Property, plant and equipment, net $ 0.5 $ 0.5 Liabilities Operating lease liabilities (current) Current operating lease liabilities $ 6.2 $ 6.1 Finance lease liabilities (current) Accrued liabilities and other current liabilities $ 0.3 $ 0.2 Operating lease liabilities (non-current) Operating lease liabilities $ 22.0 $ 23.1 Finance lease liabilities (non-current) Other long-term liabilities $ 0.3 $ 0.4 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: April 2, 2021 April 3, 2020 Operating lease weighted average remaining lease term (in years) 6.2 6.8 Operating lease weighted average discount rate 4.9 % 4.9 % Finance lease weighted average remaining lease term (in years) 3.0 3.2 Finance lease weighted average discount rate 3.8 % 3.6 % The following table provides information related to the Company’s operating and finance leases: (In millions) Three Months Ended April 2, 2021 Three Months Ended April 3, 2020 Six Months Ended April 2, 2021 Six Months Ended April 3, 2020 Total operating lease costs (a) $ 2.0 $ 1.9 $ 3.9 $ 4.0 Total finance lease costs $ — $ 0.1 $ 0.1 $ 0.1 Operating cash flows from operating leases $ 1.9 $ 2.1 $ 3.7 $ 4.1 Financing cash flows from finance leases — (0.1) 0.1 — Total cash paid for amounts included in the measurement of lease liabilities $ 1.9 $ 2.0 $ 3.8 $ 4.1 (a) Includes variable and short-term lease expense, which were immaterial for the three and six months ended April 2, 2021 and April 3, 2020. As of April 2, 2021, the present value of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows: (In millions) Fiscal years: Operating Leases Finance Leases 2021 remaining $ 3.7 $ 0.1 2022 7.2 0.2 2023 4.8 0.2 2024 4.1 0.1 2025 3.8 — Thereafter 9.4 — Total future lease payments $ 33.0 $ 0.6 Less: imputed interest (4.8) — Present value of lease liabilities $ 28.2 $ 0.6 During the first quarter of fiscal year 2021, the Company entered into a lease agreement for a manufacturing facility in the Philippines that consists of three buildings. During the second quarter of fiscal year 2021, the Company commenced leasing one of the three buildings. The leases for the other two buildings are not expected to commence until the third quarter of fiscal year 2021. These remaining two building leases have a stated term of five years and will result in an initial lease right-of-use asset and liability balance of approximately $2.4 million upon lease commencement.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS6 Months Ended
Apr. 02, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONSRELATED PARTY TRANSACTIONS Investment in Privately-Held Companies The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a holding company that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon-based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests. The investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated. During the three months ended April 2, 2021 and April 3, 2020, the Company recorded a loss on the equity investment in dpiX Holding of $(0.4) million and $(0.8) million, respectively. During the six months ended April 2, 2021 and April 3, 2020, the Company recorded (loss) income on the equity investment in dpiX Holding of $(1.9) million and $0.1 million, respectively. Income and loss on the equity investment in dpiX Holding is included in other expense, net in the condensed consolidated statements of operations. The carrying value of the equity investment in dpiX Holding was $45.6 million and $47.3 million at April 2, 2021 and October 2, 2020, respectively. During the three months ended April 2, 2021 and April 3, 2020, the Company purchased glass transistor arrays from dpiX totaling $4.1 million and $5.3 million, respectively. During the six months ended April 2, 2021 and April 3, 2020, the Company purchased glass transistor arrays from dpiX totaling $9.0 million and $10.9 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the condensed consolidated balance sheets or cost of revenues in the condensed consolidated statements of operations. As of April 2, 2021, and October 2, 2020, the Company had accounts payable to dpiX totaling $3.9 million and $4.6 million, respectively. In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. In addition the amended agreement requires the Company to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. In January 2021, the fixed cost commitment was determined and approved by the dpiX board of directors to be $11.6 million for calendar year 2021. As of April 2, 2021, the Company estimated it has fixed cost commitments of $8.7 million related to this amended agreement through the remainder of calendar year 2021. The amended agreement will continue unless the ownership structure of dpiX changes as provided in the amended agreement. The Company has determined that dpiX Holding is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to unilaterally direct the activities of dpiX Holding and therefore is not the primary beneficiary of dpiX Holding. The Company’s exposure to loss as a result of its involvement with dpiX Holding is limited to the carrying value of the Company’s investment of $45.6 million and fixed cost commitments. In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging GmbH & Co. KG (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. As of April 2, 2021, the Company has made contributions totaling $4.0 million, and has committed to contribute an additional $1.2 million as milestones are achieved, and to provide certain full-time employees to support prototyping and manufacturing activities in exchange for a 50% interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a 50% interest in VEC. During the six months ended April 2, 2021, the Company loaned $0.6 million to VEC. During the three months ended April 2, 2021, and April 3, 2020, the Company recorded loss on the equity investment in VEC of $0.2 million and $0.6 million, respectively. During the six months ended April 2, 2021 and April 3, 2020, the Company recorded loss on the equity investment in VEC of $0.5 million and $0.8 million, respectively. The Company's investment in VEC was $2.2 million and $2.5 million at April 2, 2021 and October 2, 2020, respectively.

RESTRUCTURING

RESTRUCTURING6 Months Ended
Apr. 02, 2021
Restructuring and Related Activities [Abstract]
RESTRUCTURINGRESTRUCTURING In July 2018, the Company committed to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company ceased all operations at the Santa Clara facility as of October 2, 2020, and all activities related to the closure of the facility were completed by the end of December 2020. On July 29, 2020, the Company commenced the implementation of a reduction in workforce to reduce the Company’s operating costs and address the impact of the COVID-19 pandemic. This action resulted in the reduction of the Company’s workforce by approximately 94 employees, of which nearly all were located within the United States. This reduction was in addition to the reduction in workforce associated with the closure of the Company’s Santa Clara facility. Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the three and six months ended April 2, 2021 and April 3, 2020, respectively, which predominantly relate to the Company's Medical segment: Three Months Ended Six Months Ended (In millions) Location of Restructuring Charges in Condensed Consolidated Statements of Operations April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Accelerated depreciation Cost of revenues $ 0.1 $ 0.9 $ 0.2 $ 1.2 Severance costs Selling, general and administrative 0.2 0.8 0.4 1.3 Total restructuring charges $ 0.3 $ 1.7 $ 0.6 $ 2.5

FINANCIAL DERIVATIVES AND HEDGI

FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES6 Months Ended
Apr. 02, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIESFINANCIAL DERIVATIVES AND HEDGING ACTIVITIES As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates. The Company records all derivatives on the condensed consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective, in which case the Company would test for effectiveness on a more frequent basis. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period income. The Company does not offset fair value amounts recognized for derivative instruments in its condensed consolidated balance sheets for presentation purposes. Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk. Derivatives Designated as Hedging Instruments - Cash Flow Hedges The Company previously used interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts effectively fix the LIBOR component of variable interest rate debt for a specific period of time. As of April 2, 2021, the Company had no outstanding derivatives designated as hedging instruments. The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated: Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Interest Rate Swap Contracts $ — $ (3.1) Interest expense $ — $ — Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Interest Rate Swap Contracts $ — $ (3.0) Interest expense $ — $ 0.1 Derivatives Designated as Hedging Instruments - Net Investment Hedges The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in majority-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of April 2, 2021, the Company had the following outstanding derivatives designated as net investment hedging instruments: (In millions, except number of instruments) Number of Instruments Notional Value Cross Currency Swap Contracts 3 $ 66.6 The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges: Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Cross Currency Swap Contracts $ 1.8 $ 5.0 Interest expense $ 0.3 $ 0.4 Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Cross Currency Swap Contracts $ (1.2) $ 4.3 Interest expense $ 0.7 $ 0.8 These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying condensed consolidated balance sheets where the instruments are recorded: (In millions) Derivative Assets and Liabilities Derivatives designated as net investment hedges Balance sheet location April 2, 2021 October 2, 2020 Cross Currency Swap Contracts Other current assets $ 1.2 $ 1.3 Cross Currency Swap Contracts Other long-term liabilities (3.3) (2.1) $ (2.1) $ (0.8) Balance Sheet Hedges The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, lease contracts, third-party accounts receivable and payable, and intercompany accounts receivable and payables. These forward contracts expire within 30 to 90 days. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense), net and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense), net. The Company does not and does not intend to use derivative financial instruments for speculative or trading purposes. The following table shows the notional amounts of outstanding foreign currency contracts as of April 2, 2021: Notional Value of Derivatives not Designated as Hedging Instruments: (In millions) Buy contracts Sell contract Japanese yen $ — $ 1.4 Philippine peso 4.5 — Swiss franc 0.9 — Chinese renminbi 1.4 4.7 Euro 15.2 — Total Notional Value $ 22.0 $ 6.1

FAIR VALUE

FAIR VALUE6 Months Ended
Apr. 02, 2021
Fair Value Disclosures [Abstract]
FAIR VALUEFAIR VALUE Assets/Liabilities Measured at Fair Value on a Recurring Basis The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities. As of April 2, 2021, the fair values of the Company's Convertible Notes and Senior Secured Notes, as defined in Note 10. Borrowings, were $246.5 million and $333.0 million, respectively. As of October 2, 2020, the fair values of the Company's Convertible Notes and Senior Secured Notes were $178.5 million and $312.8 million, respectively. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads. There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during the six months ended April 2, 2021. In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. Fair Value Measurements at April 2, 2021 (In millions) Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash equivalents - Money market funds $ — $ 68.9 $ — $ 68.9 Derivative assets — 1.2 — 1.2 Total assets measured at fair value $ — $ 70.1 $ — $ 70.1 Liabilities: Derivative liabilities $ — $ 3.3 $ — $ 3.3 Total liabilities measured at fair value $ — $ 3.3 $ — $ 3.3 Fair Value Measurements at October 2, 2020 (In millions) Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash equivalents - Money market funds $ — $ 72.9 $ — $ 72.9 Derivative assets — 1.1 — 1.1 Total assets measured at fair value $ — $ 74.0 $ — $ 74.0 Liabilities: Derivative liabilities $ — $ 2.1 $ — $ 2.1 Total liabilities measured at fair value $ — $ 2.1 $ — $ 2.1

INVENTORIES

INVENTORIES6 Months Ended
Apr. 02, 2021
Inventory Disclosure [Abstract]
INVENTORIESINVENTORIES The following table summarizes the Company’s inventories: (In millions) April 2, 2021 October 2, 2020 Raw materials and parts $ 167.9 $ 184.6 Work-in-process 24.7 23.9 Finished goods 55.6 63.4 Total inventories $ 248.2 $ 271.9 As a result of the economic downturn resulting from COVID-19, during the three months ended April 2, 2021, the Company discontinued certain products and wrote-down approximately $3.5 million of inventory associated with these discontinued products.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS6 Months Ended
Apr. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETSGOODWILL AND INTANGIBLE ASSETS The following table reflects goodwill by reportable operating segment: (In millions) Medical Industrial Total Balance at October 2, 2020 $ 174.4 $ 118.7 $ 293.1 Foreign currency translation adjustments 0.1 0.1 0.2 Balance at April 2, 2021 $ 174.5 $ 118.8 $ 293.3 The following table reflects the gross carrying amount and accumulated amortization of the Company’s intangible assets: April 2, 2021 October 2, 2020 (In millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired existing technology $ 75.1 $ (41.9) $ 33.2 $ 74.9 $ (37.5) $ 37.4 Patents, licenses and other 12.8 (10.3) 2.5 12.8 (9.7) 3.1 Customer contracts and supplier relationship 51.2 (27.7) 23.5 51.2 (24.2) 27.0 Total intangible assets $ 139.1 $ (79.9) $ 59.2 $ 138.9 $ (71.4) $ 67.5 Amortization expense for intangible assets was $4.3 million and $4.4 million for the three months ended April 2, 2021 and April 3, 2020, respectively and $8.5 million and $8.9 million for the six months ended April 2, 2021 and April 3, 2020, respectively.

BORROWINGS

BORROWINGS6 Months Ended
Apr. 02, 2021
Debt Disclosure [Abstract]
BORROWINGSBORROWINGS The following table summarizes the Company's short-term and long-term debt: April 2, 2021 October 2, 2020 (In millions, except for percentages) Amount Amount Contractual Interest Rate Effective Interest Rate Current maturities of long-term debt Other debt $ 2.9 $ 2.5 Total current maturities of long-term debt $ 2.9 $ 2.5 Non-current maturities of long-term debt: Asset-Based Loan $ — $ — Convertible Senior Unsecured Notes 200.0 200.0 4.0% 10.9% Senior Secured Notes 300.0 300.0 7.9% 8.2% Other debt 9.4 8.8 Total non-current maturities of long-term debt: $ 509.4 $ 508.8 Unamortized issuance costs and debt discounts Unamortized discount - Convertible Notes $ (41.6) $ (45.5) Unamortized issuance costs - Convertible Notes (4.5) (4.9) Unamortized issuance costs - Senior Secured Notes (5.3) (5.6) Total $ (51.4) $ (56.0) Total debt outstanding, net $ 460.9 $ 455.3 The following table summarizes the Company's interest expense: Three Months Ended Six Months Ended April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Contractual interest coupon and other $ 8.0 $ 4.0 $ 15.9 $ 8.6 Amortization of debt issuance costs 0.5 0.6 1.0 1.4 Amortization of debt discounts 1.9 — 3.8 — Total interest expense $ 10.4 $ 4.6 $ 20.7 $ 10.0 Convertible Senior Unsecured Notes On June 9, 2020, Varex issued $200.0 million in aggregate principal amount of 4.00% convertible senior unsecured notes due 2025 (“Convertible Notes”). The net proceeds from the issuance of the Convertible Notes, after deducting transaction fees and offering expense payable by the Company, were approximately $193.1 million. The Convertible Notes bear interest at the annual rate of 4.00%, payable semiannually on June 01 and December 01 of each year, beginning on December 01, 2020, and will mature on June 01, 2025, unless earlier converted or repurchased by us. Total interest expense related to the Convertible Notes for the three months ended April 2, 2021 was $4.2 million and was comprised of $2.0 million related to the contractual interest coupon and $2.2 million related to the amortization of the issuance costs and discount on the liability component. Total interest expense related to the Convertible Notes for the six months ended April 2, 2021 was $8.3 million and was comprised of $4.0 million related to the contractual interest coupon and $4.3 million related to the amortization of the issuance costs and discount on the liability component. Call Spread On June 4, 2020 and June 5, 2020, in connection with the offering of the Convertible Notes, Varex entered into privately negotiated convertible note hedge transactions (collectively, the “Hedge Transactions”). The Hedge Transactions cover, subject to customary anti-dilution adjustments, the number of shares of Varex common stock that initially underlie the Convertible Notes. The Hedge Transactions are expected generally to reduce the potential dilution and/or offset any cash payments Varex is required to make in excess of the principal amount due upon conversion of the Convertible Notes in the event that the market price of Varex common stock is greater than the strike price of the Hedge Transactions, which was initially $20.81 per share (subject to adjustment under the terms of the Hedge Transactions). The strike price of $20.81 corresponds to the initial conversion price of the Convertible Notes. The number of shares underlying the Hedge Transactions is 9.6 million. On June 4, 2020 and June 5, 2020, Varex also entered into privately negotiated warrant transactions (collectively, the “Warrant Transactions” and, together with the Hedge Transactions, the “Call Spread Transactions”), whereby the Company sold warrants at a higher strike price relating to the same number of shares of Varex common stock that initially underlie the Convertible Notes, subject to customary anti-dilution adjustments. The initial strike price of the warrants is $24.975 per share (subject to adjustment under the terms of the Warrant Transactions), which is 50% above the last reported sale price of Varex common stock on June 4, 2020. The Warrant Transactions could have a dilutive effect to the Company's stockholders to the extent that the market price per share of Varex common stock, as measured under the terms of the Warrant Transactions, exceeds the applicable strike price of the warrants. The number of shares underlying the Warrant Transactions is 9.6 million. The number of warrants outstanding as of April 2, 2021, was 9.6 million. Senior Secured Notes Varex issued $300.0 million aggregate principal amount of 7.875% Senior Secured Notes due 2027 (the "Senior Secured Notes") pursuant to an indenture dated September 30, 2020, among Varex, certain of its direct or indirect wholly-owned subsidiaries as guarantors and Wells Fargo Bank, National Association as trustee and collateral agent. Interest payments are paid semiannually on April 15 and October 15 of each year, beginning on April 15, 2021. Total interest expense related to the Senior Secured Notes for the three months ended April 2, 2021 was $6.1 million and was comprised of $5.9 million related to the contractual interest coupon and $0.2 million related to the amortization of issuance costs. Total interest expense related to the Senior Secured Notes for the six months ended April 2, 2021 was $12.1 million and was comprised of $11.8 million related to the contractual interest coupon and $0.3 million related to the amortization of issuance costs. Asset-Based Loan On September 30, 2020, the Company entered into a new revolving credit agreement consisting of a $100.0 million asset-based loan revolving credit facility (the “Asset-Based Loan”, or "ABL Facility"). Borrowings under the Asset-Based Loan will be expected to bear interest at floating rates based on LIBOR, or comparable rate, or a base rate, and an applicable margin based on Average Daily Excess Availability (as defined in the Asset-Based Loan Agreement). In addition, the Company is required to pay a quarterly commitment fee of 0.375% to 0.5%, based on the aggregate unused commitments under the Asset-Based Loan. The ABL Facility matures on the earlier of September 30, 2025 or 91 days prior to the maturity of the Convertible Notes, at which time all outstanding amounts under the ABL Facility will be due and payable. The aggregate commitment under our ABL Facility is $100.0 million; however, the borrowing base under the ABL Facility fluctuates from month-to-month depending on the amount of eligible accounts receivable, inventory, and real estate. As of April 2, 2021, no draws had been made on the ABL Facility.

NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS6 Months Ended
Apr. 02, 2021
Noncontrolling Interest [Abstract]
NONCONTROLLING INTERESTSNONCONTROLLING INTERESTS In April 2019, a subsidiary of Varex acquired 98.2% of the outstanding shares of common stock of Direct Conversion. The Company has subsequently acquired additional shares of Direct Conversion such that the Company now owns 98.7% of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its condensed consolidated financial statements and records the noncontrolling interest in the equity section of the Company's condensed consolidated balance sheet. Income representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's condensed consolidated statements of operations. In April 2021, the Company acquired the remaining 1.3% of noncontrolling interest for approximately $1 million. In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our condensed consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s condensed consolidated balance sheet. Income representing the noncontrolling partner's share of income from operations is included in the Company's condensed consolidated statements of operations. In April 2015, the Company acquired 73.5% of the then outstanding shares of MeVis, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis an annual recurring net compensation of €0.95 per MeVis share. At April 2, 2021, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares. Changes in noncontrolling interests were as follows: (In millions) Noncontrolling Interest Balance at October 2, 2020 $ 14.1 Net income attributable to noncontrolling interests 0.1 Balance at April 2, 2021 $ 14.2

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE6 Months Ended
Apr. 02, 2021
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARENET INCOME (LOSS) PER SHARE Basic income (loss) per common share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted income (loss) per common share reflects the effects of potentially dilutive securities, which is computed by dividing net income (loss) by the sum of the weighted average number of common shares outstanding and dilutive common shares. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share is as follows: Three Months Ended Six Months Ended (In millions, except per share amounts) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (3.2) Weighted average shares outstanding - basic 39.2 38.6 39.2 38.5 Dilutive effect of potential common shares 0.8 — — — Weighted average shares outstanding - diluted 40.0 38.6 39.2 38.5 Net income (loss) per share attributable to Varex - basic $ 0.08 $ (0.05) $ (0.09) $ (0.08) Net income (loss) per share attributable to Varex - diluted $ 0.08 $ (0.05) $ (0.09) $ (0.08) Anti-dilutive share based awards, excluded 3.0 3.0 3.1 2.8

EMPLOYEE STOCK PLANS

EMPLOYEE STOCK PLANS6 Months Ended
Apr. 02, 2021
Share-based Payment Arrangement [Abstract]
EMPLOYEE STOCK PLANSEMPLOYEE STOCK PLANS Share-Based Compensation Expense Share-based compensation expense recognized in the condensed consolidated statements of operations is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees. The table below summarizes the effect of recording share-based compensation expense and the option component of the employee stock purchase plan shares: Three Months Ended Six Months Ended (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Cost of revenues $ 0.3 $ 0.3 $ 0.6 $ 0.6 Research and development 0.8 0.6 1.4 1.2 Selling, general and administrative 2.5 2.4 5.2 4.7 Total share-based compensation expense $ 3.6 $ 3.3 $ 7.2 $ 6.5 Stock Option Activity The following table summarizes the activity for stock options under Varex’s 2020 Omnibus Stock Plan, 2017 Omnibus Stock Plan, and for participation in the 2017 Employee Stock Purchase Plan for the Company’s employees: Options Outstanding (In thousands, except per share amounts and the remaining term) Options Price Range Weighted Average Exercise Price Weighted Average Remaining Term (in years) Aggregate Intrinsic Value (1) Outstanding at October 2, 2020 2,735 $13.61 - $37.60 $ 29.23 4.5 $ — Granted 381 $25.06 - $25.06 25.06 Canceled, expired or forfeited (258) $27.77 - $37.10 28.50 Exercised — $0.00 - $0.00 — Outstanding at April 2, 2021 2,858 $13.61 - $37.60 $ 28.74 5.1 $ 1,401 Exercisable at April 2, 2021 1,809 $25.17 - $37.60 $ 30.78 3.1 $ — (1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.88 as of April 1, 2021, the last trading date of the Company's second quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date. Restricted Stock Units The following table summarizes the activity for restricted stock units under Varex’s 2020 Omnibus Stock Plan and 2017 Omnibus Stock Plan for the Company’s employees: (In thousands, except per share amounts) Number of Shares Weighted Average Grant-Date Fair Value Outstanding at October 2, 2020 955 $ 25.54 Granted 371 22.73 Vested (193) 33.67 Canceled or expired (28) 22.78 Outstanding at April 2, 2021 1,105 $ 23.29

TAXES ON INCOME

TAXES ON INCOME6 Months Ended
Apr. 02, 2021
Income Tax Disclosure [Abstract]
TAXES ON INCOMETAXES ON INCOME For the three months ended April 2, 2021, the Company recognized income tax expense of $0.0 million on $3.2 million of pre-tax income. For the three months ended April 3, 2020, the Company recognized income tax expense of $0.7 million on $1.1 million of pre-tax loss. For the six months ended April 2, 2021, the Company recognized income tax expense of $1.6 million on $1.5 million of pre-tax loss. For the six months ended April 3, 2020, the Company recognized income tax expense of $0.7 million on $2.3 million of pre-tax loss. The Company is unable to recognize a tax benefit for pre-tax book losses in the U.S. and certain foreign jurisdictions but has recognized tax expense for profitable foreign jurisdictions. The Company's tax expense for the three months ended April 2, 2021 decreased, primarily due to tax credits and benefits recorded in certain foreign jurisdiction. The Company's tax expense for the six months ended April 2, 2021 increased, compared to the prior year periods, primarily due to valuation allowances in the U.S. on disallowed interest expense deductions and losses in the U.S. and certain foreign jurisdictions for which no benefit can be recorded. The Company is maintaining its reinvestment assertion with respect to foreign earnings for the quarter ended April 2, 2021, which is that all earnings prior to fiscal year 2018 are permanently reinvested for all countries, and that all earnings for Direct Conversion, located primarily in Sweden and Finland, are also indefinitely reinvested in those countries, but post fiscal year 2017 earnings in all other countries are not permanently reinvested. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), signed into law on March 27, 2020, has resulted in significant changes to the U.S. federal corporate tax law. Additionally, several state and foreign jurisdictions in which we operate have enacted legislation that complies with or is incremental to the changes included in the CARES Act. The most significant impact of the CARES Act is the ability to carry back a net operating loss for 5 years. The Company has evaluated the other provisions of the CARES Act and does not believe it will have a material effect on the Company’s business, results of operations or financial condition.

SEGMENT INFORMATION

SEGMENT INFORMATION6 Months Ended
Apr. 02, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATIONSEGMENT INFORMATION The Company has two reportable operating segments: Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross profit. The operating and reportable segment structure provides alignment between business strategies and operating results. Description of Segments The Medical segment designs, manufactures, sells and services X-ray imaging components, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers and buckys (a component of X-ray units that holds X-ray film cassettes). These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells and services X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders and baggage screening at airports, and nondestructive testing and inspection applications used in a number of other markets. The Company's industrial products include Linatron ® X-ray linear accelerators, X-ray tubes, digital detectors and high voltage connectors. In addition, the Company licenses proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to industrial customers. Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful. Information related to the Company’s segments is as follows: Three Months Ended Six Months Ended (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Revenues Medical $ 156.6 $ 155.4 $ 295.8 $ 311.0 Industrial 46.9 41.6 84.8 86.1 Total revenues 203.5 197.0 380.6 397.1 Gross profit Medical 45.7 43.2 89.8 87.2 Industrial 18.9 14.4 32.0 31.5 Total gross profit 64.6 57.6 121.8 118.7 Total operating expenses 48.8 56.2 99.9 112.7 Interest and other expenses, net (12.6) (2.5) (23.4) (8.3) Income (loss) before taxes 3.2 (1.1) (1.5) (2.3) Income tax expense — 0.7 1.6 0.7 Net income (loss) 3.2 (1.8) (3.1) (3.0) Less: Net income attributable to noncontrolling interests 0.1 0.1 0.2 0.2 Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (3.2)

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)6 Months Ended
Apr. 02, 2021
Accounting Policies [Abstract]
Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods.
ConsolidationThese condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended 2020 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 30, 2020.
Subsequent EventsThe Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures.
Segment ReportingSegment Reporting The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15. Segment Information , for further information on the Company’s segments.
Fiscal YearFiscal Year The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2021 is the 52-week period ending October 1, 2021. Fiscal year 2020 was the 53-week period that ended on October 2, 2020. The fiscal quarters ended April 2, 2021 and April 3, 2020 were both 13-week periods. The two fiscal quarters ended April 2, 2021 and April 3, 2020 were 26 weeks and 27 weeks, respectively.
Use of EstimatesUse of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, warranties, contract liabilities, long-lived asset valuations, impairment on investments, valuation of financial instruments, and taxes on earnings. Actual results could differ from these estimates.
Cash and Cash Equivalents, Restricted CashCash and Cash Equivalents The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Restricted Cash
Concentration of RiskConcentration of Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for credit losses based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.
InvestmentsInvestments The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach, which means that distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment and classified as operating cash flows and those in excess of that amount will be treated as returns of investment and classified as investing cash flows. The Company reviews its equity investments in privately-held companies for impairment whenever events or changes in business circumstances are other than temporary and indicate that the carrying amount of the investments may not be fully recoverable. There were no impairments recorded during the three and six months ended April 2, 2021 and April 3, 2020, respectively.
Loss ContingenciesLoss Contingencies From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed.
Product WarrantyProduct Warranty The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while under warranty. The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
LeasesLeases The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.
Revenue RecognitionRevenue Recognition The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products. The Company determines revenue recognition through the following steps: • Identification of the contract, or contracts, with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations in the contract • Recognition of revenue when, or as, a performance obligation is satisfied Transaction price and allocation to performance obligations Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. Contracts and performance obligations The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations. Recognition of revenue Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer. Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer. Disaggregation of Revenue Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15. Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2. Revenue for the disaggregation of revenue by geographic region. Contract Balances Contract assets are included within the prepaid expenses and other current assets, and other assets balances in the condensed consolidated balance sheets. Contract liabilities, which also include refund obligations, are included within the accrued liabilities and other current liabilities, deferred revenues, and other long-term liabilities balances in the condensed consolidated balance sheets. Costs to Obtain or Fulfill a Customer Contract The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over more than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues. Deferred Revenues Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for which the services have not been rendered.
Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet EffectiveRecently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Measurement of Credit Losses on Financial Instruments. This pronouncement changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans and replaces the incurred loss methodology with a new, forward-looking “expected loss” model that considers the risk of loss over the asset’s contractual life, even if remote, historical experience, current conditions, and reasonable and supportable forecasts of future relevant events. The Company adopted this ASU on October 3, 2020, using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. Recent Accounting Standards or Updates Not Yet Effective In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The standard removes certain separation models in ASC 470-20 for convertible instruments, and, as a result, embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under ASC 815. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate. Further, the ASU made amendments to the earnings per share (“EPS”) guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. We are currently evaluating the impacts of this ASU on our condensed consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting, to provide optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate (e.g., LIBOR) reform on financial reporting. Adoption of the guidance is elective and is permitted from March 12, 2020 through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The Company does not expect that the new guidance will have a material impact on its financial position, results of operations or cash flows. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)6 Months Ended
Apr. 02, 2021
Accounting Policies [Abstract]
Summary of Cash and Cash Equivalents and Restricted CashCash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following: Six Months Ended April 2, 2021 Six Months Ended April 3, 2020 (In millions) Beginning of Period End of Period Beginning of Period End of Period Cash and cash equivalents $ 100.6 $ 111.1 $ 29.9 $ 24.2 Restricted cash 1.5 1.5 1.4 1.4 Cash and cash equivalents and restricted cash as reported per statement of cash flows $ 102.1 $ 112.6 $ 31.3 $ 25.6
Summary of Customers with a Significant Portion of RevenueDuring the periods presented, one of the Company's customers accounted for a significant portion of revenues, which is as follows: Three Months Ended Six Months Ended April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Canon Medical Systems Corporation 17.8 % 23.0 % 17.2% 20.9%
Schedule of Product Warranty LiabilityThe following table reflects the changes in the Company’s accrued product warranty: Six Months Ended (In millions) April 2, 2021 April 3, 2020 Accrued product warranty, at beginning of period $ 8.1 $ 8.1 New accruals charged to cost of revenues 6.1 7.2 Product warranty expenditures (6.3) (6.9) Accrued product warranty, at end of period $ 7.9 $ 8.4

REVENUE (Tables)

REVENUE (Tables)6 Months Ended
Apr. 02, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Geographic LocationThe following table disaggregates the Company’s revenue by geographic region: Three Months Ended Six Months Ended (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Americas $ 70.5 $ 62.5 $ 132.8 $ 132.8 EMEA 67.7 64.0 125.6 129.2 APAC 65.3 70.5 122.2 135.1 $ 203.5 $ 197.0 $ 380.6 $ 397.1
Summary of Contract Asset and LiabilitiesThe following table summarizes the changes in the contract assets and refund liabilities: Contract Assets Six Months Ended (In millions) April 2, 2021 April 3, 2020 Balance at beginning of fiscal year $ 24.6 $ 23.7 Costs recovered from product returns during the period (2.4) (3.0) Contract asset from shipments of products, subject to return during the period 2.9 3.4 Change in estimate (0.6) — Balance at end of period $ 24.5 $ 24.1 Contract Liabilities Six Months Ended (In millions) April 2, 2021 April 3, 2020 Balance at beginning of fiscal year $ 27.4 $ 26.4 Release of refund liability included in beginning of year refund liability (2.7) (3.3) Additions to refund liabilities 3.2 3.8 Change in estimate (0.7) — Balance at end of period $ 27.2 $ 26.9

LEASES (Tables)

LEASES (Tables)6 Months Ended
Apr. 02, 2021
Leases [Abstract]
Schedule of Supplemental Balance Sheet Information, Weighted Average Remaining Lease Terms and Discount RatesThe following table presents supplemental balance sheet information related to the Company's operating and finance leases: (In millions) Balance Sheet Location April 2, 2021 October 2, 2020 Assets Operating lease right-of-use assets Operating lease right-of-use assets $ 26.9 $ 27.7 Finance lease right-of-use assets Property, plant and equipment, net $ 0.5 $ 0.5 Liabilities Operating lease liabilities (current) Current operating lease liabilities $ 6.2 $ 6.1 Finance lease liabilities (current) Accrued liabilities and other current liabilities $ 0.3 $ 0.2 Operating lease liabilities (non-current) Operating lease liabilities $ 22.0 $ 23.1 Finance lease liabilities (non-current) Other long-term liabilities $ 0.3 $ 0.4 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: April 2, 2021 April 3, 2020 Operating lease weighted average remaining lease term (in years) 6.2 6.8 Operating lease weighted average discount rate 4.9 % 4.9 % Finance lease weighted average remaining lease term (in years) 3.0 3.2 Finance lease weighted average discount rate 3.8 % 3.6 %
Schedule of Lease Cost and Supplemental Cash Flow InformationThe following table provides information related to the Company’s operating and finance leases: (In millions) Three Months Ended April 2, 2021 Three Months Ended April 3, 2020 Six Months Ended April 2, 2021 Six Months Ended April 3, 2020 Total operating lease costs (a) $ 2.0 $ 1.9 $ 3.9 $ 4.0 Total finance lease costs $ — $ 0.1 $ 0.1 $ 0.1 Operating cash flows from operating leases $ 1.9 $ 2.1 $ 3.7 $ 4.1 Financing cash flows from finance leases — (0.1) 0.1 — Total cash paid for amounts included in the measurement of lease liabilities $ 1.9 $ 2.0 $ 3.8 $ 4.1 (a) Includes variable and short-term lease expense, which were immaterial for the three and six months ended April 2, 2021 and April 3, 2020.
Schedule of Finance Lease Liability MaturitiesAs of April 2, 2021, the present value of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows: (In millions) Fiscal years: Operating Leases Finance Leases 2021 remaining $ 3.7 $ 0.1 2022 7.2 0.2 2023 4.8 0.2 2024 4.1 0.1 2025 3.8 — Thereafter 9.4 — Total future lease payments $ 33.0 $ 0.6 Less: imputed interest (4.8) — Present value of lease liabilities $ 28.2 $ 0.6
Schedule of Operating Lease Liability MaturitiesAs of April 2, 2021, the present value of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows: (In millions) Fiscal years: Operating Leases Finance Leases 2021 remaining $ 3.7 $ 0.1 2022 7.2 0.2 2023 4.8 0.2 2024 4.1 0.1 2025 3.8 — Thereafter 9.4 — Total future lease payments $ 33.0 $ 0.6 Less: imputed interest (4.8) — Present value of lease liabilities $ 28.2 $ 0.6

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)6 Months Ended
Apr. 02, 2021
Restructuring and Related Activities [Abstract]
Summary of Restructuring Costs IncurredBelow is a detail of restructuring charges incurred during the three and six months ended April 2, 2021 and April 3, 2020, respectively, which predominantly relate to the Company's Medical segment: Three Months Ended Six Months Ended (In millions) Location of Restructuring Charges in Condensed Consolidated Statements of Operations April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Accelerated depreciation Cost of revenues $ 0.1 $ 0.9 $ 0.2 $ 1.2 Severance costs Selling, general and administrative 0.2 0.8 0.4 1.3 Total restructuring charges $ 0.3 $ 1.7 $ 0.6 $ 2.5

FINANCIAL DERIVATIVES AND HED_2

FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)6 Months Ended
Apr. 02, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Interest Rate DerivativesThe following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated: Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Interest Rate Swap Contracts $ — $ (3.1) Interest expense $ — $ — Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Interest Rate Swap Contracts $ — $ (3.0) Interest expense $ — $ 0.1
Schedule of Derivative InstrumentsAs of April 2, 2021, the Company had the following outstanding derivatives designated as net investment hedging instruments: (In millions, except number of instruments) Number of Instruments Notional Value Cross Currency Swap Contracts 3 $ 66.6 Notional Value of Derivatives not Designated as Hedging Instruments: (In millions) Buy contracts Sell contract Japanese yen $ — $ 1.4 Philippine peso 4.5 — Swiss franc 0.9 — Chinese renminbi 1.4 4.7 Euro 15.2 — Total Notional Value $ 22.0 $ 6.1
Schedule of Net Investment HedgesThe following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges: Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Cross Currency Swap Contracts $ 1.8 $ 5.0 Interest expense $ 0.3 $ 0.4 Amount of Gain (Loss) Recognized in OCI on Derivative Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Cross Currency Swap Contracts $ (1.2) $ 4.3 Interest expense $ 0.7 $ 0.8 These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying condensed consolidated balance sheets where the instruments are recorded: (In millions) Derivative Assets and Liabilities Derivatives designated as net investment hedges Balance sheet location April 2, 2021 October 2, 2020 Cross Currency Swap Contracts Other current assets $ 1.2 $ 1.3 Cross Currency Swap Contracts Other long-term liabilities (3.3) (2.1) $ (2.1) $ (0.8)

FAIR VALUE (Tables)

FAIR VALUE (Tables)6 Months Ended
Apr. 02, 2021
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring BasisIn the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. Fair Value Measurements at April 2, 2021 (In millions) Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash equivalents - Money market funds $ — $ 68.9 $ — $ 68.9 Derivative assets — 1.2 — 1.2 Total assets measured at fair value $ — $ 70.1 $ — $ 70.1 Liabilities: Derivative liabilities $ — $ 3.3 $ — $ 3.3 Total liabilities measured at fair value $ — $ 3.3 $ — $ 3.3 Fair Value Measurements at October 2, 2020 (In millions) Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash equivalents - Money market funds $ — $ 72.9 $ — $ 72.9 Derivative assets — 1.1 — 1.1 Total assets measured at fair value $ — $ 74.0 $ — $ 74.0 Liabilities: Derivative liabilities $ — $ 2.1 $ — $ 2.1 Total liabilities measured at fair value $ — $ 2.1 $ — $ 2.1
Fair Value, Assets Measured on Recurring BasisIn the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. Fair Value Measurements at April 2, 2021 (In millions) Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash equivalents - Money market funds $ — $ 68.9 $ — $ 68.9 Derivative assets — 1.2 — 1.2 Total assets measured at fair value $ — $ 70.1 $ — $ 70.1 Liabilities: Derivative liabilities $ — $ 3.3 $ — $ 3.3 Total liabilities measured at fair value $ — $ 3.3 $ — $ 3.3 Fair Value Measurements at October 2, 2020 (In millions) Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash equivalents - Money market funds $ — $ 72.9 $ — $ 72.9 Derivative assets — 1.1 — 1.1 Total assets measured at fair value $ — $ 74.0 $ — $ 74.0 Liabilities: Derivative liabilities $ — $ 2.1 $ — $ 2.1 Total liabilities measured at fair value $ — $ 2.1 $ — $ 2.1

INVENTORIES (Tables)

INVENTORIES (Tables)6 Months Ended
Apr. 02, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory, CurrentThe following table summarizes the Company’s inventories: (In millions) April 2, 2021 October 2, 2020 Raw materials and parts $ 167.9 $ 184.6 Work-in-process 24.7 23.9 Finished goods 55.6 63.4 Total inventories $ 248.2 $ 271.9

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)6 Months Ended
Apr. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of GoodwillThe following table reflects goodwill by reportable operating segment: (In millions) Medical Industrial Total Balance at October 2, 2020 $ 174.4 $ 118.7 $ 293.1 Foreign currency translation adjustments 0.1 0.1 0.2 Balance at April 2, 2021 $ 174.5 $ 118.8 $ 293.3
Schedule of Indefinite-Lived Intangible AssetsThe following table reflects the gross carrying amount and accumulated amortization of the Company’s intangible assets: April 2, 2021 October 2, 2020 (In millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired existing technology $ 75.1 $ (41.9) $ 33.2 $ 74.9 $ (37.5) $ 37.4 Patents, licenses and other 12.8 (10.3) 2.5 12.8 (9.7) 3.1 Customer contracts and supplier relationship 51.2 (27.7) 23.5 51.2 (24.2) 27.0 Total intangible assets $ 139.1 $ (79.9) $ 59.2 $ 138.9 $ (71.4) $ 67.5
Schedule of Finite-Lived Intangible AssetsThe following table reflects the gross carrying amount and accumulated amortization of the Company’s intangible assets: April 2, 2021 October 2, 2020 (In millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired existing technology $ 75.1 $ (41.9) $ 33.2 $ 74.9 $ (37.5) $ 37.4 Patents, licenses and other 12.8 (10.3) 2.5 12.8 (9.7) 3.1 Customer contracts and supplier relationship 51.2 (27.7) 23.5 51.2 (24.2) 27.0 Total intangible assets $ 139.1 $ (79.9) $ 59.2 $ 138.9 $ (71.4) $ 67.5

BORROWINGS (Tables)

BORROWINGS (Tables)6 Months Ended
Apr. 02, 2021
Debt Disclosure [Abstract]
Schedule of DebtThe following table summarizes the Company's short-term and long-term debt: April 2, 2021 October 2, 2020 (In millions, except for percentages) Amount Amount Contractual Interest Rate Effective Interest Rate Current maturities of long-term debt Other debt $ 2.9 $ 2.5 Total current maturities of long-term debt $ 2.9 $ 2.5 Non-current maturities of long-term debt: Asset-Based Loan $ — $ — Convertible Senior Unsecured Notes 200.0 200.0 4.0% 10.9% Senior Secured Notes 300.0 300.0 7.9% 8.2% Other debt 9.4 8.8 Total non-current maturities of long-term debt: $ 509.4 $ 508.8 Unamortized issuance costs and debt discounts Unamortized discount - Convertible Notes $ (41.6) $ (45.5) Unamortized issuance costs - Convertible Notes (4.5) (4.9) Unamortized issuance costs - Senior Secured Notes (5.3) (5.6) Total $ (51.4) $ (56.0) Total debt outstanding, net $ 460.9 $ 455.3
Schedule of Interest ExpenseThe following table summarizes the Company's interest expense: Three Months Ended Six Months Ended April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Contractual interest coupon and other $ 8.0 $ 4.0 $ 15.9 $ 8.6 Amortization of debt issuance costs 0.5 0.6 1.0 1.4 Amortization of debt discounts 1.9 — 3.8 — Total interest expense $ 10.4 $ 4.6 $ 20.7 $ 10.0

NONCONTROLLING INTERESTS (Table

NONCONTROLLING INTERESTS (Tables)6 Months Ended
Apr. 02, 2021
Noncontrolling Interest [Abstract]
Noncontrolling InterestChanges in noncontrolling interests were as follows: (In millions) Noncontrolling Interest Balance at October 2, 2020 $ 14.1 Net income attributable to noncontrolling interests 0.1 Balance at April 2, 2021 $ 14.2

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)6 Months Ended
Apr. 02, 2021
Earnings Per Share [Abstract]
Schedule of Loss Per Share, Basic and DilutedA reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share is as follows: Three Months Ended Six Months Ended (In millions, except per share amounts) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (3.2) Weighted average shares outstanding - basic 39.2 38.6 39.2 38.5 Dilutive effect of potential common shares 0.8 — — — Weighted average shares outstanding - diluted 40.0 38.6 39.2 38.5 Net income (loss) per share attributable to Varex - basic $ 0.08 $ (0.05) $ (0.09) $ (0.08) Net income (loss) per share attributable to Varex - diluted $ 0.08 $ (0.05) $ (0.09) $ (0.08) Anti-dilutive share based awards, excluded 3.0 3.0 3.1 2.8

EMPLOYEE STOCK PLANS (Tables)

EMPLOYEE STOCK PLANS (Tables)6 Months Ended
Apr. 02, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period CostsThe table below summarizes the effect of recording share-based compensation expense and the option component of the employee stock purchase plan shares: Three Months Ended Six Months Ended (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Cost of revenues $ 0.3 $ 0.3 $ 0.6 $ 0.6 Research and development 0.8 0.6 1.4 1.2 Selling, general and administrative 2.5 2.4 5.2 4.7 Total share-based compensation expense $ 3.6 $ 3.3 $ 7.2 $ 6.5
Schedule of Share-based Compensation, Stock Options, ActivityThe following table summarizes the activity for stock options under Varex’s 2020 Omnibus Stock Plan, 2017 Omnibus Stock Plan, and for participation in the 2017 Employee Stock Purchase Plan for the Company’s employees: Options Outstanding (In thousands, except per share amounts and the remaining term) Options Price Range Weighted Average Exercise Price Weighted Average Remaining Term (in years) Aggregate Intrinsic Value (1) Outstanding at October 2, 2020 2,735 $13.61 - $37.60 $ 29.23 4.5 $ — Granted 381 $25.06 - $25.06 25.06 Canceled, expired or forfeited (258) $27.77 - $37.10 28.50 Exercised — $0.00 - $0.00 — Outstanding at April 2, 2021 2,858 $13.61 - $37.60 $ 28.74 5.1 $ 1,401 Exercisable at April 2, 2021 1,809 $25.17 - $37.60 $ 30.78 3.1 $ — (1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.88 as of April 1, 2021, the last trading date of the Company's second quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units ActivityThe following table summarizes the activity for restricted stock units under Varex’s 2020 Omnibus Stock Plan and 2017 Omnibus Stock Plan for the Company’s employees: (In thousands, except per share amounts) Number of Shares Weighted Average Grant-Date Fair Value Outstanding at October 2, 2020 955 $ 25.54 Granted 371 22.73 Vested (193) 33.67 Canceled or expired (28) 22.78 Outstanding at April 2, 2021 1,105 $ 23.29

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)6 Months Ended
Apr. 02, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by SegmentInformation related to the Company’s segments is as follows: Three Months Ended Six Months Ended (In millions) April 2, 2021 April 3, 2020 April 2, 2021 April 3, 2020 Revenues Medical $ 156.6 $ 155.4 $ 295.8 $ 311.0 Industrial 46.9 41.6 84.8 86.1 Total revenues 203.5 197.0 380.6 397.1 Gross profit Medical 45.7 43.2 89.8 87.2 Industrial 18.9 14.4 32.0 31.5 Total gross profit 64.6 57.6 121.8 118.7 Total operating expenses 48.8 56.2 99.9 112.7 Interest and other expenses, net (12.6) (2.5) (23.4) (8.3) Income (loss) before taxes 3.2 (1.1) (1.5) (2.3) Income tax expense — 0.7 1.6 0.7 Net income (loss) 3.2 (1.8) (3.1) (3.0) Less: Net income attributable to noncontrolling interests 0.1 0.1 0.2 0.2 Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (3.2)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)6 Months Ended
Apr. 02, 2021segment
Accounting Policies [Abstract]
Number of reportable operating segments2

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020Apr. 03, 2020Sep. 27, 2019
Accounting Policies [Abstract]
Cash and cash equivalents $ 111.1 $ 100.6 $ 24.2 $ 29.9
Restricted cash1.5 1.5 1.4 1.4
Cash and cash equivalents and restricted cash as reported per statement of cash flows $ 112.6 $ 102.1 $ 25.6 $ 31.3

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) - Customer Concentration Risk - Canon Medical Systems Corporation3 Months Ended6 Months Ended12 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020Oct. 02, 2020
Revenue from Contract with Customer
Concentration Risk [Line Items]
Concentration risk, percentage17.80%23.00%17.20%20.90%
Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage14.60%12.00%

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details) - USD ($)3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Accounting Policies [Abstract]
Equity method investment, amount written off $ 0 $ 0 $ 0 $ 0

SUMMARY OF SIGNIFICANT ACCOUN_8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) - USD ($) $ in Millions6 Months Ended
Apr. 02, 2021Apr. 03, 2020
Movement in Standard Product Warranty Accrual [Roll Forward]
Accrued product warranty, at beginning of period $ 8.1 $ 8.1
New accruals charged to cost of revenues6.1 7.2
Product warranty expenditures(6.3)(6.9)
Accrued product warranty, at end of period $ 7.9 $ 8.4
Minimum
Product Warranty Liability [Line Items]
Warranty term12 months
Maximum
Product Warranty Liability [Line Items]
Warranty term24 months

REVENUE - Disaggregation of Rev

REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Disaggregation of Revenue [Line Items]
Revenues, net $ 203.5 $ 197 $ 380.6 $ 397.1
Americas
Disaggregation of Revenue [Line Items]
Revenues, net70.5 62.5 132.8 132.8
EMEA
Disaggregation of Revenue [Line Items]
Revenues, net67.7 64 125.6 129.2
APAC
Disaggregation of Revenue [Line Items]
Revenues, net65.3 70.5 122.2 135.1
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues, net $ 69.2 $ 60.2 $ 130.3 $ 128.8

REVENUE - Summary of Contract A

REVENUE - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of fiscal year $ 24.6 $ 23.7
Costs recovered from product returns during the period(2.4)(3)
Contract asset from shipments of products, subject to return during the period2.9 3.4
Change in estimate(0.6)0
Balance at end of period $ 24.5 $ 24.1 24.5 24.1
Change in Contract with Customer, Liability [Abstract]
Balance at beginning of fiscal year27.4 26.4
Release of refund liability included in beginning of year refund liability(2.7)(3.3)
Additions to refund liabilities3.2 3.8
Change in estimate(0.7)0
Balance at end of period27.2 26.9 27.2 26.9
Contract with customer, liability, revenue recognized $ 0.4 $ 1.3 $ 5.4 $ 7.4

LEASES - Schedule of Lease Righ

LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Assets
Operating lease right-of-use assets $ 26.9 $ 27.7
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]Property, plant and equipment, netProperty, plant and equipment, net
Finance lease right-of-use assets $ 0.5 $ 0.5
Liabilities
Operating lease liabilities (current) $ 6.2 $ 6.1
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]Accrued liabilities and other current liabilitiesAccrued liabilities and other current liabilities
Finance lease liabilities (current) $ 0.3 $ 0.2
Operating lease liabilities (non-current) $ 22 $ 23.1
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]Other long-term liabilitiesOther long-term liabilities
Finance lease liabilities (non-current) $ 0.3 $ 0.4

LEASES - Schedule of Weighted A

LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)Apr. 02, 2021Apr. 03, 2020
Leases [Abstract]
Operating lease weighted average remaining lease term (in years)6 years 2 months 12 days6 years 9 months 18 days
Operating lease weighted average discount rate4.90%4.90%
Finance lease weighted average remaining lease term (in years)3 years3 years 2 months 12 days
Finance lease weighted average discount rate3.80%3.60%

LEASES - Schedule of Operating

LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Leases [Abstract]
Total operating lease costs $ 2 $ 1.9 $ 3.9 $ 4
Total finance lease costs0 0.1 0.1 0.1
Operating cash flows from operating leases1.9 2.1 3.7 4.1
Financing cash flows from finance leases0 (0.1)0.1 0
Total cash paid for amounts included in the measurement of lease liabilities $ 1.9 $ 2 $ 3.8 $ 4.1

LEASES - Schedule of Operatin_2

LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details) $ in MillionsApr. 02, 2021USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021 remaining $ 3.7
20227.2
20234.8
20244.1
20253.8
Thereafter9.4
Total future lease payments33
Less: imputed interest(4.8)
Present value of lease liabilities28.2
Finance Lease, Liability, Payment, Due [Abstract]
2021 remaining0.1
20220.2
20230.2
20240.1
20250
Thereafter0
Total future lease payments0.6
Less: imputed interest0
Present value of lease liabilities $ 0.6

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Millions3 Months Ended
Jul. 02, 2021USD ($)Apr. 02, 2021tradingDaybuildingJan. 01, 2021building
Lessee, Lease, Description [Line Items]
Number of buildings, lease agreements entered | building3
Number of Buildings, lease agreements commenced | building1
Number of buildings, lease not yet commenced | tradingDay2
Lease not yet commenced, term5 years
Scenario, Forecast
Leases [Abstract]
Lease not yet commenced, expected lease right-of-use asset and liability | $ $ 2.4
Lessee, Lease, Description [Line Items]
Lease not yet commenced, expected lease right-of-use asset and liability | $ $ 2.4

RELATED PARTY TRANSACTIONS - In

RELATED PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details) - USD ($) $ in Millions1 Months Ended3 Months Ended6 Months Ended24 Months Ended29 Months Ended
Oct. 31, 2013Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020Dec. 31, 2021Apr. 02, 2021Oct. 02, 2020Nov. 30, 2018
Related Party Transaction [Line Items]
(Loss) income from equity method investments $ (2.5) $ (0.7)
Equity Method Investee
Related Party Transaction [Line Items]
Due from Joint Ventures $ 0.6 $ 0.6 $ 0.6
Equity Method Investee | Dpi X LLC
Related Party Transaction [Line Items]
Equity method investment, ownership percentage100.00%100.00%100.00%
dpiX Holding | Equity Method Investee
Related Party Transaction [Line Items]
Equity method investment, ownership percentage40.00%40.00%40.00%
(Loss) income from equity method investments $ (0.4) $ (0.8) $ (1.9)0.1
Equity method investments45.6 45.6 $ 45.6 $ 47.3
Purchases from related party4.1 5.3 9 10.9
Accounts payable, related parties3.9 3.9 3.9 4.6
Percentage of manufacturing capacity50.00%
Percentage of fixed costs50.00%
dpiX Holding | Equity Method Investee | Fixed Cost Commitments
Related Party Transaction [Line Items]
Purchases from related party8.7
dpiX Holding | Equity Method Investee | Scenario, Forecast | Fixed Cost Commitments
Related Party Transaction [Line Items]
Purchases from related party $ 11.6
VEC Imaging GmbH & Co. KG | Equity Method Investee
Related Party Transaction [Line Items]
Equity method investment, ownership percentage50.00%
(Loss) income from equity method investments0.2 $ 0.6 0.5 $ 0.8
Equity method investments2.2 $ 2.2 2.2 $ 2.5
Payments to acquire equity method investments $ 1.2 $ 4

RESTRUCTURING - Narrative (Deta

RESTRUCTURING - Narrative (Details)Jul. 29, 2020employee
Restructuring and Related Activities [Abstract]
Expected reduction of number of employees94

RESTRUCTURING - Summary of Rest

RESTRUCTURING - Summary of Restructuring Cost Incurred (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Restructuring and Related Activities [Abstract]
Accelerated depreciation $ 0.1 $ 0.9 $ 0.2 $ 1.2
Severance costs0.2 0.8 0.4 1.3
Total restructuring charges $ 0.3 $ 1.7 $ 0.6 $ 2.5

FINANCIAL DERIVATIVES AND HED_3

FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Derivative [Line Items]
Amount of gain (loss) recognized in OCI on derivative $ 0 $ (2.3) $ 0 $ (2.3)
Interest Rate Swap Contracts
Derivative [Line Items]
Amount of gain (loss) recognized in OCI on derivative0 (3.1)0 (3)
Cross Currency Swap Contracts
Derivative [Line Items]
Amount of gain (loss) recognized in OCI on derivative1.8 5 (1.2)4.3
Interest expense | Interest Rate Swap Contracts
Derivative [Line Items]
Amount of gain (loss) reclassified from accumulated OCI into income0 0 0 0.1
Interest expense | Cross Currency Swap Contracts
Derivative [Line Items]
Amount of gain (loss) reclassified from accumulated OCI into income $ 0.3 $ 0.4 $ 0.7 $ 0.8

FINANCIAL DERIVATIVES AND HED_4

FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) - Derivatives designated as cash flow hedges - Designated as Hedging Instrument - Cross Currency Swap Contracts $ in MillionsApr. 02, 2021USD ($)derivativeContract
Derivative [Line Items]
Number of Instruments | derivativeContract3
Notional Value | $ $ 66.6

FINANCIAL DERIVATIVES AND HED_5

FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) - Derivatives designated as cash flow hedges - Designated as Hedging Instrument - Cross Currency Swap Contracts - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Derivative [Line Items]
Derivative liabilities fair value, gross $ (2.1) $ (0.8)
Other current assets
Derivative [Line Items]
Derivative assets fair value, gross1.2 1.3
Other long-term liabilities
Derivative [Line Items]
Derivative liabilities fair value, gross $ (3.3) $ (2.1)

FINANCIAL DERIVATIVES AND HED_6

FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details) $ in Millions6 Months Ended
Apr. 02, 2021USD ($)
Derivative [Line Items]
Minimum remaining maturity of foreign currency derivatives30 days
Maximum remaining maturity of foreign currency derivatives90 days
Buy contracts | Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Notional Value $ 22
Buy contracts | Designated as Hedging Instrument | Japanese yen | Foreign Exchange Contract
Derivative [Line Items]
Notional Value0
Buy contracts | Designated as Hedging Instrument | Philippine peso | Foreign Exchange Contract
Derivative [Line Items]
Notional Value4.5
Buy contracts | Designated as Hedging Instrument | Swiss franc | Foreign Exchange Contract
Derivative [Line Items]
Notional Value0.9
Buy contracts | Designated as Hedging Instrument | Chinese renminbi | Foreign Exchange Contract
Derivative [Line Items]
Notional Value1.4
Buy contracts | Designated as Hedging Instrument | Euro | Foreign Exchange Contract
Derivative [Line Items]
Notional Value15.2
Sell contract | Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Notional Value6.1
Sell contract | Designated as Hedging Instrument | Japanese yen | Foreign Exchange Contract
Derivative [Line Items]
Notional Value1.4
Sell contract | Designated as Hedging Instrument | Philippine peso | Foreign Exchange Contract
Derivative [Line Items]
Notional Value0
Sell contract | Designated as Hedging Instrument | Swiss franc | Foreign Exchange Contract
Derivative [Line Items]
Notional Value0
Sell contract | Designated as Hedging Instrument | Chinese renminbi | Foreign Exchange Contract
Derivative [Line Items]
Notional Value4.7
Sell contract | Designated as Hedging Instrument | Euro | Foreign Exchange Contract
Derivative [Line Items]
Notional Value $ 0

FAIR VALUE - Narrative (Details

FAIR VALUE - Narrative (Details) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Convertible Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value $ 246.5 $ 178.5
Secured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value $ 333 $ 312.8

FAIR VALUE - Schedule of Fair V

FAIR VALUE - Schedule of Fair Value Inputs (Details) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Assets:
Cash equivalents - Money market funds $ 68.9 $ 72.9
Derivative assets1.2 1.1
Total assets measured at fair value70.1 74
Liabilities:
Derivative liabilities3.3 2.1
Total liabilities measured at fair value3.3 2.1
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Cash equivalents - Money market funds0 0
Derivative assets0 0
Total assets measured at fair value0 0
Liabilities:
Derivative liabilities0 0
Total liabilities measured at fair value0 0
Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents - Money market funds68.9 72.9
Derivative assets1.2 1.1
Total assets measured at fair value70.1 74
Liabilities:
Derivative liabilities3.3 2.1
Total liabilities measured at fair value3.3 2.1
Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents - Money market funds0 0
Derivative assets0 0
Total assets measured at fair value0 0
Liabilities:
Derivative liabilities0 0
Total liabilities measured at fair value $ 0 $ 0

INVENTORIES - Summary of Invent

INVENTORIES - Summary of Inventory (Details) - USD ($) $ in MillionsApr. 02, 2021Oct. 02, 2020
Inventory Disclosure [Abstract]
Raw materials and parts $ 167.9 $ 184.6
Work-in-process24.7 23.9
Finished goods55.6 63.4
Total inventories $ 248.2 $ 271.9

INVENTORIES - Narrative (Detail

INVENTORIES - Narrative (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 02, 2021Apr. 03, 2020
Inventory [Line Items]
Inventory write-down $ 3.5 $ 0
COVID-19
Inventory [Line Items]
Inventory write-down $ 3.5

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) $ in Millions6 Months Ended
Apr. 02, 2021USD ($)
Goodwill [Roll Forward]
Balance at October 2, 2020 $ 293.1
Foreign currency translation adjustments0.2
Balance at April 2, 2021293.3
Medical
Goodwill [Roll Forward]
Balance at October 2, 2020174.4
Foreign currency translation adjustments0.1
Balance at April 2, 2021174.5
Industrial
Goodwill [Roll Forward]
Balance at October 2, 2020118.7
Foreign currency translation adjustments0.1
Balance at April 2, 2021 $ 118.8

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020Oct. 02, 2020
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization $ (79.9) $ (79.9) $ (71.4)
Total intangible assets139.1 139.1 138.9
Total intangible assets, net59.2 59.2 67.5
Amortization of intangible assets4.3 $ 4.4 8.5 $ 8.9
Acquired existing technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross75.1 75.1 74.9
Accumulated amortization(41.9)(41.9)(37.5)
Total intangible assets with finite lives, net carrying amount33.2 33.2 37.4
Patents, licenses and other
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross12.8 12.8 12.8
Accumulated amortization(10.3)(10.3)(9.7)
Total intangible assets with finite lives, net carrying amount2.5 2.5 3.1
Customer contracts and supplier relationship
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross51.2 51.2 51.2
Accumulated amortization(27.7)(27.7)(24.2)
Total intangible assets with finite lives, net carrying amount $ 23.5 $ 23.5 $ 27

BORROWINGS - Schedule of Debt (

BORROWINGS - Schedule of Debt (Details) - USD ($) $ in Millions6 Months Ended
Apr. 02, 2021Oct. 02, 2020Sep. 30, 2020
Current maturities of long-term debt
Current maturities of long-term debt $ 2.9 $ 2.5
Non-current maturities of long-term debt:
Long-term debt excluding current maturities, gross509.4 508.8
Unamortized issuance costs and debt discounts
Unamortized issuance costs and debt discounts, total(51.4)(56)
Total debt outstanding, net460.9 455.3
Convertible Debt
Non-current maturities of long-term debt:
Long-term debt excluding current maturities, gross $ 200 200
Contractual Interest Rate4.00%
Effective Interest Rate10.90%
Unamortized issuance costs and debt discounts
Unamortized discount $ (41.6)(45.5)
Debt issuance costs(4.5)(4.9)
Senior Secured Notes | Secured Debt
Non-current maturities of long-term debt:
Long-term debt excluding current maturities, gross $ 300 300
Contractual Interest Rate7.90%7.875%
Effective Interest Rate8.20%
Unamortized issuance costs and debt discounts
Debt issuance costs $ (5.3)(5.6)
Other debt
Current maturities of long-term debt
Current maturities of long-term debt2.9 2.5
Non-current maturities of long-term debt:
Long-term debt excluding current maturities, gross9.4 8.8
Revolving Credit Facility | Asset-Based Loan
Non-current maturities of long-term debt:
Long-term debt excluding current maturities, gross $ 0 $ 0

BORROWINGS - Schedule of Intere

BORROWINGS - Schedule of Interest Expense (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Debt Disclosure [Abstract]
Contractual interest coupon and other $ 8 $ 4 $ 15.9 $ 8.6
Amortization of debt issuance costs0.5 0.6 1 1.4
Amortization of debt discounts1.9 0 3.8 0
Total interest expense $ 10.4 $ 4.6 $ 20.7 $ 10

BORROWINGS - Convertible Notes

BORROWINGS - Convertible Notes Narrative (Details) - USD ($)Jun. 09, 2020Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Debt Instrument [Line Items]
Contractual interest coupon and other $ 8,000,000 $ 4,000,000 $ 15,900,000 $ 8,600,000
Amortization of debt discounts $ 1,900,000 $ 0 $ 3,800,000 $ 0
Convertible Debt
Debt Instrument [Line Items]
Contractual Interest Rate4.00%4.00%
Convertible Debt | Convertible Notes
Debt Instrument [Line Items]
Face amount $ 200,000,000
Contractual Interest Rate4.00%
Proceeds from issuance of convertible debt $ 193,100,000
Interest expense $ 4,200,000 $ 8,300,000
Contractual interest coupon and other2,000,000 4,000,000
Amortization of debt discounts $ 2,200,000 $ 4,300,000

BORROWINGS - Call Spread Narrat

BORROWINGS - Call Spread Narrative (Details) equity_instrument in MillionsApr. 02, 2021equity_instrumentJun. 05, 2020equity_instrumentJun. 04, 2020$ / shares
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share) $ 24.975
Percent increase of strike price over sale price50.00%
Convertible Notes | Convertible Debt
Debt Instrument [Line Items]
Conversion price (in dollars per share) $ 20.81
Number of equity instruments for convertible debt | equity_instrument9.6 9.6

BORROWINGS - Senior Secured Not

BORROWINGS - Senior Secured Notes Narrative (Details) - USD ($)3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020Sep. 30, 2020
Debt Instrument [Line Items]
Contractual interest coupon and other $ 8,000,000 $ 4,000,000 $ 15,900,000 $ 8,600,000
Amortization of debt issuance costs $ 500,000 $ 600,000 $ 1,000,000 $ 1,400,000
Senior Secured Notes | Secured Debt
Debt Instrument [Line Items]
Face amount $ 300,000,000
Contractual Interest Rate7.90%7.90%7.875%
Interest expense $ 6,100,000 $ 12,100,000
Contractual interest coupon and other5,900,000 11,800,000
Amortization of debt issuance costs $ 200,000 $ 300,000

BORROWINGS - Asset-Based Loan N

BORROWINGS - Asset-Based Loan Narrative (Details) - Revolving Credit Facility - Asset-Based Loan - Secured Debt - USD ($)Sep. 30, 2020Apr. 02, 2021
Debt Instrument [Line Items]
Maximum borrowing capacity $ 100,000,000 $ 100,000,000
Long-term line of credit $ 0
Minimum
Debt Instrument [Line Items]
Used capacity, commitment fee percentage0.375%
Maximum
Debt Instrument [Line Items]
Used capacity, commitment fee percentage0.50%

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details) shares in Millions, $ in MillionsApr. 30, 2021USD ($)Aug. 31, 2015€ / sharesApr. 02, 2021USD ($)sharesApr. 30, 2019Sep. 30, 2018Apr. 30, 2015
Noncontrolling Interest [Line Items]
Percentage of voting interests acquired26.30%
Annual recurring compensation (in euros per share) | € / shares € 0.95
Temporary equity, shares outstanding (in shares) | shares0.5
Noncontrolling Interest
Balance at October 2, 2020 $ 14.1
Less: Net income attributable to noncontrolling interests0.1
Balance at April 2, 2021 $ 14.2
Subsequent Event
Noncontrolling Interest [Line Items]
Payments to noncontrolling interests $ 1
Joint Venture In Saudi Arabia
Noncontrolling Interest [Line Items]
Majority voting rights, percent75.00%
Noncontrolling interest, ownership percentage by noncontrolling owners25.00%
Direct Conversion AB
Noncontrolling Interest [Line Items]
Percentage of voting interests acquired98.70%98.20%
Direct Conversion AB | Subsequent Event
Noncontrolling Interest [Line Items]
Percentage of voting interests acquired1.30%
MeVis Medical Solutions AG (MeVis)
Noncontrolling Interest [Line Items]
Percentage of voting interests acquired73.50%

NET INCOME (LOSS) PER SHARE - R

NET INCOME (LOSS) PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Earnings Per Share [Abstract]
Net income (loss) attributable to Varex $ 3.1 $ (1.9) $ (3.3) $ (3.2)
Weighted average common shares outstanding - basic (in shares)39.2 38.6 39.2 38.5
Dilutive effect of potential common shares (in shares)0.8 0 0 0
Weighted average common shares outstanding - diluted (in shares)40 38.6 39.2 38.5
Net (loss) earnings per share attributable to Varex - basic (in USD per share) $ 0.08 $ (0.05) $ (0.09) $ (0.08)
Net (loss) earnings per share attributable to Varex - diluted (in USD per share) $ 0.08 $ (0.05) $ (0.09) $ (0.08)
Anti-dilutive employee shared based awards, excluded (in shares)3 3 3.1 2.8

NET INCOME (LOSS) PER SHARE - N

NET INCOME (LOSS) PER SHARE - Narrative (Details) - Convertible DebtApr. 02, 2021Jun. 09, 2020
Debt Instrument [Line Items]
Contractual Interest Rate4.00%
Convertible Notes
Debt Instrument [Line Items]
Contractual Interest Rate4.00%

EMPLOYEE STOCK PLANS - Share-ba

EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense $ 3.6 $ 3.3 $ 7.2 $ 6.5
Cost of revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense0.3 0.3 0.6 0.6
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense0.8 0.6 1.4 1.2
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense $ 2.5 $ 2.4 $ 5.2 $ 4.7

EMPLOYEE STOCK PLANS - Stock Op

EMPLOYEE STOCK PLANS - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands3 Months Ended6 Months Ended
Jan. 01, 2021Apr. 02, 2021Apr. 01, 2021
Options
Options, outstanding, beginning balance (in shares)2,735 2,735
Options, grants in period (in shares)381
Options, canceled, forfeited and expired in period (in shares)(258)
Options, exercises in period (in shares)0
Options, outstanding, ending balance (in shares)2,858
Options, exercisable (in shares)1,809
Weighted Average Exercise Price
Options, outstanding, weighted average exercise price, beginning (in USD per share) $ 29.23 $ 29.23
Options, grants in period, weighted average exercise price (in USD per share)25.06
Options, canceled, forfeited and expired in period, weighted average exercise price (in USD per share)28.50
Options, exercises in period, weighted average exercise price (in USD per share)0
Options, outstanding, weighted average exercise price, ending (in USD per share)28.74
Options, exercisable, weighted average exercise price (in USD per share) $ 30.78
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options, outstanding, weighted average remaining contractual term (in years)4 years 6 months5 years 1 month 6 days
Options, exercisable, weighted average remaining contractual term (in years)3 years 1 month 6 days
Options, outstanding, intrinsic value $ 0 $ 1,401
Options, exercisable, intrinsic value $ 0
Share price (in USD per share) $ 20.88
Minimum
Price Range
Outstanding at period beginning (in USD per share) $ 13.61 $ 13.61
Granted (in USD per share)25.06
Canceled, expired or forfeited (in USD per share)27.77
Exercised (in USD per share)0
Outstanding at period ending (in USD per share)13.61
Exercisable at January 3, 2020 (in USD per share)25.17
Maximum
Price Range
Outstanding at period beginning (in USD per share) $ 37.60 37.60
Granted (in USD per share)25.06
Canceled, expired or forfeited (in USD per share)37.10
Exercised (in USD per share)0
Outstanding at period ending (in USD per share)37.60
Exercisable at January 3, 2020 (in USD per share) $ 37.60

EMPLOYEE STOCK PLANS - Restrict

EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) shares in Thousands6 Months Ended
Apr. 02, 2021$ / sharesshares
Number of Shares
Restricted stock units, nonvested, beginning balance, number of shares (in shares) | shares955
Restricted stock units, grants in period (in shares) | shares371
Restricted stock units, vested in period (in shares) | shares(193)
Restricted stock units, canceled or expired in period (in shares) | shares(28)
Restricted stock units, nonvested, ending balance, number of shares (in shares) | shares1,105
Weighted Average Grant-Date Fair Value
Restricted stock units, nonvested, beginning of period, weighted average grant date fair value (in USD per share) | $ / shares $ 25.54
Restricted stock units, grants in period, weighted average grant date fair value (in USD per share) | $ / shares22.73
Restricted stock units, vested in period, weighted average grant date fair value (in USD per share) | $ / shares33.67
Restricted stock units, canceled or expired, weighted average grant date fair value (in USD per share) | $ / shares22.78
Restricted stock units, nonvested, end of period, weighted average grant date fair value (in USD per share) | $ / shares $ 23.29

TAXES ON INCOME - Narrative (De

TAXES ON INCOME - Narrative (Details) - USD ($) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021Apr. 03, 2020Apr. 02, 2021Apr. 03, 2020
Income Tax Disclosure [Abstract]
Income tax expense $ 0 $ 0.7 $ 1.6 $ 0.7
Loss before taxes3.2 $ (1.1)(1.5) $ (2.3)
Deferred tax liabilities of undistributed foreign earnings $ 0.1 $ 0.1

SEGMENT INFORMATION - Income St

SEGMENT INFORMATION - Income Statement Information (Details) $ in Millions3 Months Ended6 Months Ended
Apr. 02, 2021USD ($)Apr. 03, 2020USD ($)Apr. 02, 2021USD ($)segmentApr. 03, 2020USD ($)
Segment Reporting Information [Line Items]
Number of reportable operating segments | segment2
Revenues, net $ 203.5 $ 197 $ 380.6 $ 397.1
Gross profit64.6 57.6 121.8 118.7
Total operating expenses48.8 56.2 99.9 112.7
Interest and other expenses, net(12.6)(2.5)(23.4)(8.3)
Income (loss) before taxes3.2 (1.1)(1.5)(2.3)
Income tax expense0 0.7 1.6 0.7
Net income (loss)3.2 (1.8)(3.1)(3)
Less: Net income attributable to noncontrolling interests0.1 0.1 0.2 0.2
Net income (loss) attributable to Varex3.1 (1.9)(3.3)(3.2)
Medical
Segment Reporting Information [Line Items]
Revenues, net156.6 155.4 295.8 311
Gross profit45.7 43.2 89.8 87.2
Industrial
Segment Reporting Information [Line Items]
Revenues, net46.9 41.6 84.8 86.1
Gross profit $ 18.9 $ 14.4 $ 32 $ 31.5